NCT05523778

Brief Summary

The purpose of this study is to compare the clinical efficacy and economic cost of enucleation after placement of pancreatic duct stents before surgery with that of direct enucleation alone, and to evaluate its safety and feasibility.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
78

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Feb 2023

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 16, 2022

Completed
15 days until next milestone

First Posted

Study publicly available on registry

August 31, 2022

Completed
5 months until next milestone

Study Start

First participant enrolled

February 6, 2023

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2024

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2025

Completed
Last Updated

November 2, 2023

Status Verified

July 1, 2023

Enrollment Period

1.8 years

First QC Date

August 16, 2022

Last Update Submit

October 31, 2023

Conditions

Keywords

Pancreatic enucleationPancreatic duct stentRegular pancreatectomyHealth economics evaluation

Outcome Measures

Primary Outcomes (1)

  • Rate of POPF within 3 months after EN.

    Postoperative clinically relevant pancreatic fistula in this study adopts the definition proposed by the international pancreatic surgery research group (ISGPS)

    3 days to 3 months after enucleation (or the extubation time),up to 6 month after inclusion

Secondary Outcomes (10)

  • Rate of postoperative abdominal infection within 3 weeks after EN

    3 days to 3 weeks after enucleation (or the extubation time),,up to 6 month after inclusion

  • Rate of postoperative delayed gastric emptying within 3 weeks after EN

    3 days to 3 weeks after enucleation (or the extubation time)

  • Rate of postoperative hemorrhagepostpancreatectomy haemorrhage within 3 weeks after EN

    1 days to 3 weeks after enucleation (or the extubation time),,up to 6 month after inclusion

  • Rate of postoperative dyspepsia within 6 months after EN

    2 weeks to 6 months after enucleation,,up to 6 month after inclusion

  • Rate of postoperative lung infection within 3 weeks after EN

    1 days to 3 weeks after enucleation (or the extubation time),,up to 6 month after inclusion

  • +5 more secondary outcomes

Study Arms (2)

Stented EN

EXPERIMENTAL

Patients are placed the pancreatic duct stent by endoscopist 1day or several hours before the enucleation surgery.

Procedure: placement of pancreatic duct stents before enucleation surgery

Direct EN

ACTIVE COMPARATOR

Patients will receive enucleation surgery directly following normal procedure

Procedure: Direct enucleation surgery

Interventions

Advance placement of pancreatic stents endoscopically

Stented EN

Patients will receive direct enucleation surgery

Direct EN

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • The clinical qualitative diagnosis of insulinoma was clear;
  • The localization diagnosis was clear, and it was determined that the tumor was single, located in the head and neck;
  • The distance between the tumor and the main pancreatic duct was determined to be ≤ 2mm by preoperative imaging (enhanced CT, MRI, etc.);
  • Truly informed and voluntarily participate in this study.

You may not qualify if:

  • Maximum diameter of the tumor \>2cm proved pathologically
  • Severe cardiopulmonary complications before operation
  • Combined with other known tumor diseases
  • Insulinoma is invasive or has suspicious metastatic lesions
  • Previous upper abdominal surgery history
  • Refusal or inability to cooperate in the study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Peking Union Medical College Hospital

Beijing, Beijing Municipality, 100730, China

RECRUITING

Related Publications (1)

  • Gao R, Yin B, Jin J, Tian X, Zhang Y, Wei J, Cao F, Wang Z, Ma Z, Wang M, Gou S, Cong L, Xu Q, Wu W, Zhao Y. Preoperative pancreatic stent placement before the enucleation of insulinoma located in the head and neck of the pancreas in proximity to the main pancreatic duct: study protocol for a multicentre randomised clinical trial in Chinese tertiary medical centres. BMJ Open. 2024 Apr 2;14(4):e078516. doi: 10.1136/bmjopen-2023-078516.

MeSH Terms

Conditions

Insulinoma

Condition Hierarchy (Ancestors)

Adenoma, Islet CellAdenomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsPancreatic NeoplasmsDigestive System NeoplasmsNeoplasms by SiteEndocrine Gland NeoplasmsDigestive System DiseasesPancreatic DiseasesEndocrine System Diseases

Central Study Contacts

Qiang Xu, Doctor

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Masking Details
Outcome assessors are kept blinded to participant group allocation. Objective clinical data are provided to independent assessors with blindness of allocation. With clear definition for each endpoints, assessors are able to make grading for complications in primary and secondary endpoints
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 16, 2022

First Posted

August 31, 2022

Study Start

February 6, 2023

Primary Completion

December 1, 2024

Study Completion

December 1, 2025

Last Updated

November 2, 2023

Record last verified: 2023-07

Data Sharing

IPD Sharing
Will share

Data obtained through this study may be provided to qualified researchers with academic interest in the surgical treatment of insulinoma. Data shared will be coded, with no PHI included. Approval of the request and execution of all applicable agreements (i.e. a material transfer agreement) are prerequisites to the sharing of data with the requesting party.

Shared Documents
STUDY PROTOCOL, SAP, ICF
Time Frame
Data requests can be submitted starting 12 months after article publication and the data will be made accessible for up to 24 months. Extensions will be considered on a case-by-case basis."Data requests can be submitted starting 9 months after article publication and the data will be made accessible for up to 24 months. Extensions will be considered on a case-by-case basis.
Access Criteria
Access to trial IPD can be requested by qualified researchers engaging in independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA).

Locations